Edition:
India

Lipocine Inc (LPCN.OQ)

LPCN.OQ on NASDAQ Stock Exchange Capital Market

3.63USD
17 Nov 2017
Change (% chg)

$-0.22 (-5.71%)
Prev Close
$3.85
Open
$3.55
Day's High
$3.68
Day's Low
$3.55
Volume
62,557
Avg. Vol
34,103
52-wk High
$5.32
52-wk Low
$3.15

Select another date:

Fri, Nov 17 2017

BRIEF-Lipocine says ‍FDA assigned a new prescription drug user fee act goal date of May 8, 2018 for Tlando​

* U.S. FDA extends review for Tlando™; advisory committee meeting date of January 10, 2018 remains unchanged

BRIEF-Lipocine Inc Q3 loss per share $0.22

* Lipocine announces financial and operational results for the third quarter and nine months ended September 30, 2017

BRIEF-Lipocine says FDA has scheduled bone, reproductive and urologic drugs advisory committee meeting on January 10, 2018

* Lipocine -‍ announced FDA has scheduled bone, reproductive and urologic drugs advisory committee meeting on January 10, 2018 to discuss NDA for Tlando​

BRIEF-Lipocine Inc files for mixed shelf of up to $150 million

* Lipocine Inc files for mixed shelf of up to $150 million - SEC filing‍​ Source text for Eikon: (http://bit.ly/2zlVhiU) Further company coverage:

BRIEF-Lipocine - ‍PTAB of USPTO issued a motions decision in interference case between Clarus Therapeutics and Lipocine Inc​

* Lipocine - ‍ PTAB of USPTO issued a motions decision based on each party's motions in interference case between Clarus Therapeutics and Lipocine Inc​

BRIEF-Lipocine announces FDA Advisory Committee meeting for TLANDO

* Lipocine Inc - advisory committee meeting date has not been finalized but will occur prior to PDUFA goal date of February 8, 2018 Source text for Eikon: Further company coverage:

BRIEF-Lipocine announces FDA acknowledgement of Tlando NDA resubmission

* Lipocine announces FDA acknowledgement of Tlando (LPCN 1021) NDA resubmission; PDUFA goal date, February 8, 2018

BRIEF-Lipocine ‍resubmits NDA for oral testosterone product candidate

* Says ‍resubmits NDA for its oral testosterone product candidate, LPCN 1021, for treatment of hypogonadism​

BRIEF-Lipocine posts Q2 loss per share $0.31

* Lipocine announces financial and operational results for the second quarter and six months ended June 30, 2017

BRIEF-Lipocine announces submission of special protocol assessment request to FDA on LPCN 1107, an oral alternative for prevention of preterm birth

* Lipocine Inc - Announces submission of special protocol assessment request to FDA on LPCN 1107, an oral alternative for prevention of preterm birth Source text for Eikon: Further company coverage:

Select another date: